Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock are in focus as the companies are nearing to strike U.S. pricing deals for ...

Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

Novo Nordisk's new CEO said he was confident in the company's pipeline of obesity drugs, but that buying Metsera would allow ...

Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...

Eli Lilly (NYSE: LLY) shares rose 6% in the premarket on Thursday after the drugmaker beat Wall Street expectations with its ...

Eli Lilly’s fair value estimate has recently been raised from $891.62 to $919.33. This reflects a modest increase in the company’s intrinsic valuation amid evolving market sentiment. The upward ...

Insulin costs have declined over the past two years, and additional price cuts are expected in 2026. Medicare will lower prices for several diabetes drugs, including Januvia and Jardiance. Federal and ...

Obesity drugs have become an increasingly popular method of weight loss but most are not covered by insurance for that ...

Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded ...

Company cuts 9,000 jobs and lowers profit forecast as Wegovy sales slow. Q3 operating profit down 30% on competition ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

The healthcare industry has proven to be a resilient place for investors to put cash to work over the years. If you are ...